Loyal fully enrolls 60 senior dogs in its first LOY-002 pilot study

Loyal/LOY-002

Loyal completed enrollment of its first LOY-002 pilot study with 60 companion dogs aged 7 to 10 and weighing 14 to 180 pounds. The trial tests a daily tablet formulation and validates the study design for a later pivotal trial, marking the first time dogs received LOY-002 in a clinical setting.

• 60 dogs fully enrolled, achieving target on schedule to support the subsequent pivotal trial.
• Dogs range from 7 to 10 years old and 14 to 180 pounds, representing diverse companion dog populations.
• Primary objective observes how the drug affects biomarkers associated with aging in dogs.
• Timely enrollment validates operational feasibility of the larger pivotal study design.